# IBTROZI (taletrectinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/taletrectinib

> The PDUFA target action date for IBTROZI (taletrectinib), sponsored by Nuvation Bio Inc. (NUVB), is January 4, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the IBTROZI (taletrectinib) PDUFA date?

The PDUFA target action date for IBTROZI (taletrectinib), sponsored by Nuvation Bio Inc. (NUVB), is January 4, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "In September 2026, Nuvation Bio announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for IBTROZI, four months ahead of the January 4, 2027, target action date." Last confirmed November 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/taletrectinib)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-447321, https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/taletrectinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | IBTROZI (taletrectinib) |
| Codes | AB-106, DS-6051B |
| Sponsor | Nuvation Bio Inc. (NUVB) https://sec-api.dev/companies/nuvb/catalysts |
| Indications | with advanced ros1+ nsclc, advanced ros1+ nsclc, [Non-small Cell Lung Cancer (NSCLC)](https://sec-api.dev/indications/non-small-cell-lung-cancer-nsclc), [Non Small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer) |
| Modality | small_molecule |
| FDA designations | breakthrough, orphan, priority review |

## Timeline

### June 7, 2024: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2025-03-06, last confirmed 2025-03-06.
- SEC Form 10-K (accession 0000950170-25-034903): "These pooled results utilized a June 7, 2024 data cut off and were used to support our U.S. NDA submission that was submitted in October 2024." https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm

### Oct 2024: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: with advanced ROS1+ NSCLC.
- First seen 2025-03-06, last confirmed 2025-05-07.
- SEC Form 10-Q (accession 0000950170-25-065712): "Based on pooled results of the TRUST-I and TRUST-II studies, we submitted a New Drug Application ("NDA") for taletrectinib to the U.S. FDA in October 2024 for the treatment of patients with advanced ROS1+ NSCLC (line agnostic, full approval)." https://www.sec.gov/Archives/edgar/data/1811063/000095017025065712/nuvb-20250331.htm
- SEC Form 10-K (accession 0000950170-25-034903): "Based on pooled results of the TRUST-I and TRUST-II studies, the Company submitted a New Drug Application ("NDA") for taletrectinib to the U.S. FDA in October 2024 for the treatment of patients with advanced ROS1+ NSCLC who either have or have not previously been treated with a ROS1 tyrosine kinase inhibitor ("TKI")." https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm

### Dec 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-03-06, last confirmed 2025-03-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-048529): "In December 2024, the U.S FDA accepted and granted Priority Review to the Companys NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval)." https://www.sec.gov/Archives/edgar/data/1811063/000119312525048529/d910737dex991.htm

### June 11, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-06-11, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-174954): "On June 11, 2025, we announced that the FDA approved IBTROZI (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)." https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/d909051dex991.htm
- SEC Form 8-K (accession 0001193125-25-139164): "On June 11, 2025, Nuvation Bio Inc. (the "Company") announced that the U.S. Food and Drug Administration has approved IBTROZITM (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer." https://www.sec.gov/Archives/edgar/data/1811063/000119312525139164/d932856d8k.htm
- SEC Form 10-Q (accession 0001193125-26-447238): "On June 11, 2025, we announced that the FDA approved IBTROZI for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC." https://www.sec.gov/Archives/edgar/data/1811063/000119312526447238/nuvb-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-336646): "On June 11, 2025, we announced that the FDA approved IBTROZI for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer ("NSCLC")." https://www.sec.gov/Archives/edgar/data/1811063/000119312526336646/nuvb-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-203964): "On June 11, 2025, we announced that the FDA approved IBTROZI for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer ("NSCLC")." https://www.sec.gov/Archives/edgar/data/1811063/000119312526203964/nuvb-20260331.htm
- SEC Form 10-K (accession 0001193125-26-085584): "On June 11, 2025, we announced that the FDA approved IBTROZI for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer ("NSCLC")." https://www.sec.gov/Archives/edgar/data/1811063/000119312526085584/nuvb-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-009826): "On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-na&iuml;ve and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved IBTROZI for the treatment of adult patients with locally advanced or metastatic" https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/d947742dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-447321): "In June 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC." https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-174954): "In June 2025, the Company received U.S. FDA approval for IBTROZI (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC." https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/d909051dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-174954): "In June 2025, the Company received $200 million as part of non-dilutive financing agreements with Sagard Healthcare Partners, including $150 million in royalty interest financing and $50 million under a term loan following U.S. FDA approval of IBTROZI." https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/d909051dex991.htm
- SEC Form 10-Q (accession 0001193125-26-447238): "In June 2025, we received FDA approval to commercialize IBTROZI in the U.S. for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC, and we initiated a commercial launch of IBTROZI in the U.S. in that indication." https://www.sec.gov/Archives/edgar/data/1811063/000119312526447238/nuvb-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-336646): "In June 2025, we received FDA approval to commercialize IBTROZI in the U.S. for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC, and we initiated a commercial launch of IBTROZI in the U.S. in that indication." https://www.sec.gov/Archives/edgar/data/1811063/000119312526336646/nuvb-20260630.htm

### June 11, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Non Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04919811 (Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Nuvation Bio Inc.." https://clinicaltrials.gov/study/NCT04919811

### June 23, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: advanced ROS1+ NSCLC.
- First seen 2025-03-06, last confirmed 2026-06-29.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-114908): "The PDUFA goal date of June 23, 2025 positions Nuvation Bio to commercialize taletrectinib in the U.S., if approved, in mid-2025." https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-114908): "FDA has accepted and granted Priority Review to Nuvation Bios NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval) and assigned a PDUFA goal date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-048529): "The PDUFA goal date of June 23, 2025, positions Nuvation Bio to commercialize taletrectinib in the U.S., if approved, in mid-2025." https://www.sec.gov/Archives/edgar/data/1811063/000119312525048529/d910737dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-048529): "FDA has accepted and granted Priority Review to Nuvation Bios NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval) and assigned a PDUFA goal date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/1811063/000119312525048529/d910737dex991.htm
- SEC Form 10-Q (accession 0000950170-25-065712): "The FDA accepted for priority review our NDA for taletrectinib for the treatment of advanced ROS1+ NSCLC with a target PDUFA date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/1811063/000095017025065712/nuvb-20250331.htm
- SEC Form 10-K (accession 0000950170-25-034903): "The FDA accepted for priority review our NDA for taletrectinib for the treatment of advanced ROS1+ NSCLC with a target PDUFA date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm
- SEC prospectus (424B) (accession 0001193125-26-286494): "In December 2024, the FDA accepted the NDA and assigned a Prescription Drug User Fee Action target action date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/1811063/000119312526286494/d125210d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-281815): "In December 2024, the FDA accepted the NDA and assigned a Prescription Drug User Fee Action target action date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/1811063/000119312526281815/d125210d424b5.htm
- SEC Form 10-Q (accession 0000950170-25-065712): "On December 22, 2024, the FDA accepted the NDA for Priority Review and assigned a Prescription Drug User Fee Act ("PDUFA") target action date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/1811063/000095017025065712/nuvb-20250331.htm
- SEC Form 10-K (accession 0000950170-25-034903): "On December 22, 2024, the FDA accepted the NDA and assigned a Prescription Drug User Fee Action ("PDUFA") target action date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm
- SEC Form 10-K (accession 0000950170-25-034903): "On December 22, 2024, the FDA accepted the NDA and assigned a PDUFA target action date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm
- SEC Form 10-K (accession 0000950170-25-034903): "In December 2024, the FDA accepted the NDA with Priority Review designation and assigned a Prescription Drug User Fee Action ("PDUFA") target action date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm

### Sep 2026: label expansion decision

- Status: completed, approved. Date confidence: month.
- First seen 2026-11-04, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-447321): "In September 2026, Nuvation Bio announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for IBTROZI, four months ahead of the January 4, 2027, target action date." https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm
- SEC Form 10-Q (accession 0001193125-26-447238): "In September 2026, we announced that the FDA approved a supplemental New Drug Application ("sNDA") for IBTROZI® (taletrectinib)." https://www.sec.gov/Archives/edgar/data/1811063/000119312526447238/nuvb-20260930.htm

### January 4, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-08-06, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-447321): "In September 2026, Nuvation Bio announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for IBTROZI, four months ahead of the January 4, 2027, target action date." https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm
- SEC Form 10-Q (accession 0001193125-26-336646): "In May 2026, we announced the FDA had accepted a supplemental New Drug Application with updated data for IBTROZI in both TKI-naïve and TKI-pretreated advanced ROS1+ NSCLC with a target action date of January 4, 2027." https://www.sec.gov/Archives/edgar/data/1811063/000119312526336646/nuvb-20260630.htm

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06564324 (A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." https://clinicaltrials.gov/study/NCT06564324

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06564324 (A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." https://clinicaltrials.gov/study/NCT06564324

### Aug to Nov 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07154706 (Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-30 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." https://clinicaltrials.gov/study/NCT07154706

### August 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07154706 (Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-30 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." https://clinicaltrials.gov/study/NCT07154706

## Same indication

- [Datopotamab deruxtecan (dato-dxd)](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) (AZN)
- [Domvanalimab](https://sec-api.dev/pdufa/domvanalimab) (RCUS)
- [Iph5201 + durvalumab + standard chemotherapy](https://sec-api.dev/pdufa/iph5201-durvalumab-standard-chemotherapy) (IPHA)
- [Nai + pembrolizumab](https://sec-api.dev/pdufa/nai-pembrolizumab) (IBRX)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [REGN10597](https://sec-api.dev/pdufa/regn10597) (REGN)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin) (ABBV)
- [Ubamatamab](https://sec-api.dev/pdufa/ubamatamab) (REGN)

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/taletrectinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IBTROZI (taletrectinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/taletrectinib

```bibtex
@misc{secapidev_pdufa_taletrectinib_20261116,
  title        = {IBTROZI (taletrectinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/taletrectinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_taletrectinib_20261116","title":"IBTROZI (taletrectinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/taletrectinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
